The irruption of immunotherapy based on the Immune Checkpoint Blockade (ICB) with anti-PD-(L)1 monoclonal antibodies was considered a revolution in the treatment of advanced lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.